Blood pressure responses and metabolic effects of hydrochlorothiazide and atenolol

Steven M. Smith, Yan Gong, Stephen T Turner, Rhonda M. Cooper-Dehoff, Amber L. Beitelshees, Arlene B. Chapman, Eric Boerwinkle, Kent R Bailey, Julie A. Johnson, John G. Gums

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background Thiazides and Β-blockers cause adverse metabolic effects (AMEs), but whether these effects share predictors with blood pressure (BP) response is unknown. We aimed to determine whether AMEs are correlated with BP response in uncomplicated hypertensives. Methods In a multicenter, open-label, parallel-group trial, we enrolled 569 persons, aged 17-65, with random assignment to 9 weeks of daily hydrochlorothiazide (HCTZ) or atenolol monotherapy, followed by 9 weeks of add-on therapy with the alternate agent. Measurements included home BP, averaged over 1 week, weight and fasting levels of serum glucose, low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides, and uric acid (UA) before and after monotherapy and after add-on therapy. Results Increases in UA correlated with reductions in systolic BP (SBP) (r = 0.18; P = 0.003) and diastolic BP (DBP) (r = 0.20; P = 0.001) following HCTZ monotherapy and add-on therapy (r = 0.27 and r = 0.21, respectively; both P< 0.001). After adjustment for age, race, gender, and baseline body mass index (BMI), only the correlation between UA and DBP response became nonsignificant. Reductions in HDL correlated with systolic response following atenolol monotherapy (r = 0.18; P = 0.002) and with systolic and diastolic response following add-on therapy (r = 0.30 and r = 0.24, respectively; both P< 0.0001). These correlations remained significant after covariate adjustment. BP responses were not correlated with changes in glucose, LDL, triglycerides, or weight following either therapy. Conclusions BP response correlated with changes in UA following HCTZ therapy and HDL following atenolol therapy. No other significant correlations were observed between BP response and AMEs, suggesting that these effects generally do not share predictors. Patients should be monitored for AMEs, regardless of BP response.

Original languageEnglish (US)
Pages (from-to)359-365
Number of pages7
JournalAmerican Journal of Hypertension
Volume25
Issue number3
DOIs
StatePublished - Mar 2012

Fingerprint

Hydrochlorothiazide
Atenolol
Blood Pressure
Uric Acid
HDL Lipoproteins
Therapeutics
Thiazides
Social Adjustment
Weights and Measures
Glucose
LDL Lipoproteins
Fasting
Body Mass Index

Keywords

  • β-blockers
  • atenolol
  • blood pressure
  • hydrochlorothiazide
  • hypertension
  • metabolic effects
  • thiazide diuretics

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Smith, S. M., Gong, Y., Turner, S. T., Cooper-Dehoff, R. M., Beitelshees, A. L., Chapman, A. B., ... Gums, J. G. (2012). Blood pressure responses and metabolic effects of hydrochlorothiazide and atenolol. American Journal of Hypertension, 25(3), 359-365. https://doi.org/10.1038/ajh.2011.215

Blood pressure responses and metabolic effects of hydrochlorothiazide and atenolol. / Smith, Steven M.; Gong, Yan; Turner, Stephen T; Cooper-Dehoff, Rhonda M.; Beitelshees, Amber L.; Chapman, Arlene B.; Boerwinkle, Eric; Bailey, Kent R; Johnson, Julie A.; Gums, John G.

In: American Journal of Hypertension, Vol. 25, No. 3, 03.2012, p. 359-365.

Research output: Contribution to journalArticle

Smith, SM, Gong, Y, Turner, ST, Cooper-Dehoff, RM, Beitelshees, AL, Chapman, AB, Boerwinkle, E, Bailey, KR, Johnson, JA & Gums, JG 2012, 'Blood pressure responses and metabolic effects of hydrochlorothiazide and atenolol', American Journal of Hypertension, vol. 25, no. 3, pp. 359-365. https://doi.org/10.1038/ajh.2011.215
Smith, Steven M. ; Gong, Yan ; Turner, Stephen T ; Cooper-Dehoff, Rhonda M. ; Beitelshees, Amber L. ; Chapman, Arlene B. ; Boerwinkle, Eric ; Bailey, Kent R ; Johnson, Julie A. ; Gums, John G. / Blood pressure responses and metabolic effects of hydrochlorothiazide and atenolol. In: American Journal of Hypertension. 2012 ; Vol. 25, No. 3. pp. 359-365.
@article{34e0fc4c814e45e3aa88f113ffb84087,
title = "Blood pressure responses and metabolic effects of hydrochlorothiazide and atenolol",
abstract = "Background Thiazides and Β-blockers cause adverse metabolic effects (AMEs), but whether these effects share predictors with blood pressure (BP) response is unknown. We aimed to determine whether AMEs are correlated with BP response in uncomplicated hypertensives. Methods In a multicenter, open-label, parallel-group trial, we enrolled 569 persons, aged 17-65, with random assignment to 9 weeks of daily hydrochlorothiazide (HCTZ) or atenolol monotherapy, followed by 9 weeks of add-on therapy with the alternate agent. Measurements included home BP, averaged over 1 week, weight and fasting levels of serum glucose, low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides, and uric acid (UA) before and after monotherapy and after add-on therapy. Results Increases in UA correlated with reductions in systolic BP (SBP) (r = 0.18; P = 0.003) and diastolic BP (DBP) (r = 0.20; P = 0.001) following HCTZ monotherapy and add-on therapy (r = 0.27 and r = 0.21, respectively; both P< 0.001). After adjustment for age, race, gender, and baseline body mass index (BMI), only the correlation between UA and DBP response became nonsignificant. Reductions in HDL correlated with systolic response following atenolol monotherapy (r = 0.18; P = 0.002) and with systolic and diastolic response following add-on therapy (r = 0.30 and r = 0.24, respectively; both P< 0.0001). These correlations remained significant after covariate adjustment. BP responses were not correlated with changes in glucose, LDL, triglycerides, or weight following either therapy. Conclusions BP response correlated with changes in UA following HCTZ therapy and HDL following atenolol therapy. No other significant correlations were observed between BP response and AMEs, suggesting that these effects generally do not share predictors. Patients should be monitored for AMEs, regardless of BP response.",
keywords = "β-blockers, atenolol, blood pressure, hydrochlorothiazide, hypertension, metabolic effects, thiazide diuretics",
author = "Smith, {Steven M.} and Yan Gong and Turner, {Stephen T} and Cooper-Dehoff, {Rhonda M.} and Beitelshees, {Amber L.} and Chapman, {Arlene B.} and Eric Boerwinkle and Bailey, {Kent R} and Johnson, {Julie A.} and Gums, {John G.}",
year = "2012",
month = "3",
doi = "10.1038/ajh.2011.215",
language = "English (US)",
volume = "25",
pages = "359--365",
journal = "American Journal of Hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Blood pressure responses and metabolic effects of hydrochlorothiazide and atenolol

AU - Smith, Steven M.

AU - Gong, Yan

AU - Turner, Stephen T

AU - Cooper-Dehoff, Rhonda M.

AU - Beitelshees, Amber L.

AU - Chapman, Arlene B.

AU - Boerwinkle, Eric

AU - Bailey, Kent R

AU - Johnson, Julie A.

AU - Gums, John G.

PY - 2012/3

Y1 - 2012/3

N2 - Background Thiazides and Β-blockers cause adverse metabolic effects (AMEs), but whether these effects share predictors with blood pressure (BP) response is unknown. We aimed to determine whether AMEs are correlated with BP response in uncomplicated hypertensives. Methods In a multicenter, open-label, parallel-group trial, we enrolled 569 persons, aged 17-65, with random assignment to 9 weeks of daily hydrochlorothiazide (HCTZ) or atenolol monotherapy, followed by 9 weeks of add-on therapy with the alternate agent. Measurements included home BP, averaged over 1 week, weight and fasting levels of serum glucose, low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides, and uric acid (UA) before and after monotherapy and after add-on therapy. Results Increases in UA correlated with reductions in systolic BP (SBP) (r = 0.18; P = 0.003) and diastolic BP (DBP) (r = 0.20; P = 0.001) following HCTZ monotherapy and add-on therapy (r = 0.27 and r = 0.21, respectively; both P< 0.001). After adjustment for age, race, gender, and baseline body mass index (BMI), only the correlation between UA and DBP response became nonsignificant. Reductions in HDL correlated with systolic response following atenolol monotherapy (r = 0.18; P = 0.002) and with systolic and diastolic response following add-on therapy (r = 0.30 and r = 0.24, respectively; both P< 0.0001). These correlations remained significant after covariate adjustment. BP responses were not correlated with changes in glucose, LDL, triglycerides, or weight following either therapy. Conclusions BP response correlated with changes in UA following HCTZ therapy and HDL following atenolol therapy. No other significant correlations were observed between BP response and AMEs, suggesting that these effects generally do not share predictors. Patients should be monitored for AMEs, regardless of BP response.

AB - Background Thiazides and Β-blockers cause adverse metabolic effects (AMEs), but whether these effects share predictors with blood pressure (BP) response is unknown. We aimed to determine whether AMEs are correlated with BP response in uncomplicated hypertensives. Methods In a multicenter, open-label, parallel-group trial, we enrolled 569 persons, aged 17-65, with random assignment to 9 weeks of daily hydrochlorothiazide (HCTZ) or atenolol monotherapy, followed by 9 weeks of add-on therapy with the alternate agent. Measurements included home BP, averaged over 1 week, weight and fasting levels of serum glucose, low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides, and uric acid (UA) before and after monotherapy and after add-on therapy. Results Increases in UA correlated with reductions in systolic BP (SBP) (r = 0.18; P = 0.003) and diastolic BP (DBP) (r = 0.20; P = 0.001) following HCTZ monotherapy and add-on therapy (r = 0.27 and r = 0.21, respectively; both P< 0.001). After adjustment for age, race, gender, and baseline body mass index (BMI), only the correlation between UA and DBP response became nonsignificant. Reductions in HDL correlated with systolic response following atenolol monotherapy (r = 0.18; P = 0.002) and with systolic and diastolic response following add-on therapy (r = 0.30 and r = 0.24, respectively; both P< 0.0001). These correlations remained significant after covariate adjustment. BP responses were not correlated with changes in glucose, LDL, triglycerides, or weight following either therapy. Conclusions BP response correlated with changes in UA following HCTZ therapy and HDL following atenolol therapy. No other significant correlations were observed between BP response and AMEs, suggesting that these effects generally do not share predictors. Patients should be monitored for AMEs, regardless of BP response.

KW - β-blockers

KW - atenolol

KW - blood pressure

KW - hydrochlorothiazide

KW - hypertension

KW - metabolic effects

KW - thiazide diuretics

UR - http://www.scopus.com/inward/record.url?scp=84857039982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857039982&partnerID=8YFLogxK

U2 - 10.1038/ajh.2011.215

DO - 10.1038/ajh.2011.215

M3 - Article

VL - 25

SP - 359

EP - 365

JO - American Journal of Hypertension

JF - American Journal of Hypertension

SN - 0895-7061

IS - 3

ER -